Table 3.
Performance of biomarkers and/or clinical data for prediction IgAN remission status.
| AUC (95% Cl) a (n=262) | |
|---|---|
| Univariable models of biomarkers | |
| Urinary sCD163 at biopsy | 0.732 (0.658-0.807) |
| Urinary IL6 at biopsy | 0.661 (0.586-0.735) |
| Urinary MCP-1 at biopsy | 0.638 (0.560-0.716) |
| Clinical models | |
| Clinical data at biopsy b | 0.768 (0.688-0.849) |
| Clinical data at biopsy + MEST-C c | 0.769 (0.690-0.848) |
| Models containing clinical data and biomarkers | |
| Clinical data at biopsy + MEST-C + urinary sCD163 | 0.788 (0.717-0.860) |
| Clinical data at biopsy + MEST-C + urinary IL6 | 0.774 (0.697-0.851) |
| Clinical data at biopsy + MEST-C + urinary MCP-1 | 0.778 (0.704-0.851) |
| Models containing clinical data and multiple biomarkers | |
| Clinical data at biopsy + MEST-C + urinary sCD163 + IL6 + MCP-1 | 0.784 (0.711-0.858) |
AUC, Area under the Curve of ROC; Cl, confidence interval; MCP-1, monocyte chemoattractant protein-1; MEST-C, histologic score based on mesangial hypercellularity, the presence of endocapillary proliferation, segmental glomerulosclerosis/adhesion, and severity of tubular atrophy/interstitial fibrosis, and crescents formation.
a
Expressed as AUC, continuous biomarkers were used in the model.
b
Comprising mean arterial blood pressure, 24 hour proteinuria, and estimated glomerular filtration rate at biopsy.
c
Oxford histologic classification.